Ayvakit (avapritinib) Tablets
Ayvakit is a tyrosine kinase inhibitor used for the treatment of patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutation.
Blueprint Medicines offers 5 financial assistance programs for patients who have been prescribed Ayvakit:
YourBlueprint Co-Pay Assistance Program
Eligible patients who have private or commercial insurance may pay as little as $0 per prescription of Ayvakit.
YourBlueprint Patient Assistance Program
Patients who are uninsured, or who have limited insurance, may be eligible to receive Ayvakit for free. Patients must reside in the United States and meet the financial eligibility criteria.
QuickStart Program
Eligible patients may be able to receive a 15-day supply of medication at no cost through this program while waiting to get their insurance coverage.
Coverage Interruption Program
Patients who change their insurance or have a temporary interruption in their insurance coverage may be eligible to get a temporary no-cost supply of the medication.
Ayvakit Dose Exchange Program
Patients who had their dose of Ayvakit adjusted by their doctor can trade their remaining medication for the new dose at no cost.
Gleevec (imatinib mesylate) Tablets
Gleevec is a kinase inhibitor used for the treatment of patients with Kit (CD117)-positive unresectable, recurrent and/or metastatic GIST, and as an adjuvant treatment.
Novartis Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Gleevec:
Gleevec Patient Support Program
This program offers patient counselors, educational information, and financial assistance resources, such as the Gleevec $10 Co-Pay Card.
Novartis Oncology Universal Co-pay Program
Patients with private insurance may pay only $10 for a 30-day supply of Gleevec, with a maximum of $10,630 for a 30-day supply and up to an annual maximum of $30,000.
Novartis Patient Assistance Foundation
Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Gleevec for free through the Novartis Patient Assistance Foundation. To be eligible for financial assistance, the patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Gleevec for free until prescription drug coverage becomes available to them.
Qinlock (ripretinib) Tablets
Qinlock is a kinase inhibitor used for the treatment of adults with advanced GIST who have received 3 or more previous kinase inhibitors, including imatinib.
Deciphera offers 2 financial assistance programs for patients who have been prescribed Qinlock:
Commercial Copay Program
This program will cover all out-of-pocket drug costs so that eligible patients who have commercial or private insurance pay as little as $0 copay.
Patient Assistance Program
Eligible patients who do not have insurance, or whose coverage does not cover the cost of Qinlock, may qualify to receive Qinlock for free through this program.
Stivarga (regorafenib) Tablets
Stivarga is a kinase inhibitor used for the treatment of patients with locally advanced, unresectable, or metastatic GIST after treatment with imatinib or sunitinib malate.
Bayer offers 2 financial assistance programs for patients using Stivarga:
STIVARGA $0 Co-Pay Program
Through this program, patients with private insurance will have a $0 copay for Stivarga, up to $25,000 per patient annually.
Bayer US Patient Assistance Foundation
This foundation provides free medicine for patients who are prescribed a Bayer medication and are uninsured or underinsured and meet certain eligibility criteria.
Sutent (sunitinib malate) Capsules
Sutent is a kinase inhibitor used for the treatment of patients with GIST.
Pfizer Oncology Together offers 2 financial assistance programs for patients using Sutent:
Pfizer Oncology Together Co-Pay Savings Program
This Pfizer program assists eligible patients with private insurance so that their copay for Sutent is $0 monthly, with a maximum savings of up to $25,000 annually.
Pfizer Patient Assistance Program
This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Sutent for free or at a savings. Eligible patients with government insurance who cannot find independent charitable foundation support may receive Sutent for free.
Table. Drugs Prescribed for GIST (Gastrointestestinal Stromal Tumor)
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Ayvakit (avapritinib) Tablets
- Blueprint Medicines
- Treatment of unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutation
- YourBlueprint Co-Pay Assistance Program
888-258-7768
YourBlueprint Patient Assistance Program
888-258-7768
QuickStart Program
888-258-7768
Coverage Interruption Program
888-258-7768
Ayvakit Dose Exchange Program
888-258-7768
- Gleevec (imatinib mesylate) Tablets
- Novartis
- Treatment of patients with
Kit (CD117)-positive
unresectable, recurrent and/
or metastatic GIST
As adjuvant treatment after surgery to remove Kit (CD117)-positive GIST - Gleevec Patient Support Program
866-453-3832
Novartis Oncology Universal Co-pay Program
877-577-7756
Novartis Patient Assistance Foundation
800-277-2254
- Qinlock (ripretinib) Tablets
- Deciphera
- Treatment of adults with advanced GIST who have received 3 or more kinase inhibitors, including imatinib
- Commercial Copay Program
833-432-2237
Patient Assistance Program
833-432-2237
- Stivarga (regorafenib) Tablets
- Bayer
- Treatment of patients with locally advanced, unresectable or metastatic GIST
- STIVARGA $0 Co-Pay Program
866-581-4992
Bayer US Patient Assistance Foundation
866-228-7723
- Sutent (sunitinib malate) Capsules
- Pfizer
- Treatment of GIST
- Pfizer Oncology Together Co-Pay Savings Program
877-744-5675
Pfizer Patient Assistance Program
877-744-5675